Compare CGEM & FINV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CGEM | FINV |
|---|---|---|
| Founded | 2016 | 2007 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance: Consumer Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 2020 | 2017 |
| Metric | CGEM | FINV |
|---|---|---|
| Price | $20.59 | $4.37 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 8 | 1 |
| Target Price | ★ $30.13 | $12.10 |
| AVG Volume (30 Days) | ★ 576.3K | 391.7K |
| Earning Date | 05-11-2026 | 05-19-2026 |
| Dividend Yield | N/A | ★ 6.09% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $5.20 | $10.58 |
| P/E Ratio | ★ N/A | $3.87 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.68 | $4.35 |
| 52 Week High | $21.00 | $9.73 |
| Indicator | CGEM | FINV |
|---|---|---|
| Relative Strength Index (RSI) | 72.03 | 31.51 |
| Support Level | $16.40 | N/A |
| Resistance Level | N/A | $5.07 |
| Average True Range (ATR) | 1.18 | 0.14 |
| MACD | 0.31 | -0.06 |
| Stochastic Oscillator | 96.18 | 1.23 |
Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.
FinVolution Group is a provider of online consumer finance in China. The company offers various loan products, making financial services available to borrowers anytime, anywhere; designs a loan transaction process, and offers tailored risk-based pricing. It offers short-term loans to borrowers to meet immediate credit needs while allowing them to gradually establish their credit history through activities on the company's platform. The company generates revenues from fees charged to borrowers. The Group's long-lived assets are located in the PRC, and its revenues are derived from within the PRC.